Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Receptor activator of NF‐κB ligand (RANKL) has been identified as requisite for osteoclastogenesis. To elucidate the molecular mechanism that conducts its catabolic action on bone, the effect of 1α,25 dihydroxyvitamin D 3 (1α,25(OH)2 D 3) on osteoclastogenesis and RANKL mRNA expression was examined by coculture, RT‐PCR and nuclear run‐on studies. By accelerating the transcription rate of the RANKL gene in SaOS2 osteoblastic cells, 1α,25(OH)2 D 3 enhanced in vitro osteoclast formation from peripheral monocytes. Cloning and characterization of the 5′‐flanking region of the human RANKL gene revealed that the basic promoter comprises inverted TATA‐ and CAAT‐boxes flanked by RUNX2 binding sites. Both electrophoresis mobility shift assay (EMSA) and transfection studies demonstrated that 1α,25(OH)2 D 3 activated human RANKL promoter through vitamin D responsive elements (VDRE) located at −1584/−1570 by binding VDR and RXRα heterodimers in a ligand‐dependent manner. The results provide direct evidence that 1α,25(OH)2 D 3 augments osteoclastogenesis by transactivating the human RANKL gene in osteoblastic cells through VDRE. J. Cell. Biochem. 89: 771–777, 2003. © 2003 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“RANKL/ RANK interactions also regulate T-cell/dendritic cell communication [Anderson et al., 1997], dendritic cell survival [Anderson et al., 1997; Darnay et al., 1998], and lymph node formation [Kong et al., 1999].”
BackgroundA homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Minireview: The OPG/RANKL/RANK System
Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515 · cited 3×
“, 1991] and receptor activator of NF-kB ligand (RANKL) [Lacey et al., 1998; Yasuda et al., 1998; Khosla, 2001].”
BackgroundWei, S., Wang, M. W.-H., Teitelbaum, S. L., & Ross, F. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m104957200 · Cited by 202
RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa, S., & Kitazawa, R. (2002) · The Journal of Pathology · doi:10.1002/path.1199 · Cited by 141 · cited 5×
“, 1999], cancerassociated osteolytic diseases [Kitazawa and Kitazawa, 2002c] and rheumatoid arthritis [Takayanagi et al.”
BackgroundSelf-citation
Cited by
Vitamin D for health: a global perspective
Hossein-nezhad, A., & Holick, M. F. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.05.011 · Cited by 1,298
Dusso, A. S., Brown, A. J., & Slatopolsky, E. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00336.2004 · Cited by 1,148
Noncalcemic Actions of Vitamin D Receptor Ligands
Nagpal, S., Na, S., & Rathnachalam, R. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0002 · Cited by 961
Where is the vitamin D receptor?
Wang, Y., Zhu, J., & DeLuca, H. F. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.04.001 · Cited by 629
Pike, J. W., & Meyer, M. B. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.02.007 · Cited by 394
Panda, D. K., Miao, D., Bolivar, I., Li, J., Huo, R., Hendy, G. N., & Goltzman, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310271200 · Cited by 393
Spencer, G. J., Utting, J. C., Etheridge, S. L., Arnett, T. R., & Genever, P. G. (2006) · Journal of Cell Science · doi:10.1242/jcs.02883 · Cited by 334
Mori, T., Miyamoto, T., Yoshida, H., Asakawa, M., Kawasumi, M., Kobayashi, T., Morioka, H., Chiba, K., Toyama, Y., & Yoshimura, A. (2011) · International Immunology · doi:10.1093/intimm/dxr077 · Cited by 328
Nuclear Receptors and Their Selective Pharmacologic Modulators
Burris, T. P., Solt, L. A., Wang, Y., Crumbley, C., Banerjee, S., Griffett, K., Lundasen, T., Hughes, T., & Kojetin, D. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006833 · Cited by 283
Rogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215
Calcium intake, calcium homeostasis and health
Pu, F., Chen, N., & Xue, S. (2016) · Food Science and Human Wellness · doi:10.1016/j.fshw.2016.01.001 · Cited by 173
Pike, J. W., & Meyer, M. B. (2012) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2012.03.004 · Cited by 86
Teplyuk, N. M., Zhang, Y., Lou, Y., Hawse, J. R., Hassan, M. Q., Teplyuk, V. I., Pratap, J., Galindo, M., Stein, J. L., Stein, G. S., et al. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0270 · Cited by 52
Metadata
- Authors
- Kitazawa, S., Kajimoto, K., Kondo, T., & Kitazawa, R.
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2003-06-16
- Volume
- 89
- Issue
- 4
- Pages
- 771-777
- ISSN
- 0730-2312 (ISSN-L)
- 1097-4644
- OpenAlex
- W2091773006
- Cited by
- 147
- References
- 6
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.